These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. Predictors of oncological outcome after resection of locally recurrent renal cell carcinoma. Margulis V; McDonald M; Tamboli P; Swanson DA; Wood CG J Urol; 2009 May; 181(5):2044-51. PubMed ID: 19286220 [TBL] [Abstract][Full Text] [Related]
8. Prognostic significance of perinephric fat infiltration and tumor size in renal cell carcinoma. Yoo C; Song C; Hong JH; Kim CS; Ahn H J Urol; 2008 Aug; 180(2):486-91; discussion 491. PubMed ID: 18550101 [TBL] [Abstract][Full Text] [Related]
9. Impact of cytoreductive nephrectomy on eligibility for systemic treatment and effects on survival: are surgical complications or disease related factors responsible? O'Malley RL; Brewer KA; Hayn MH; Kim HL; Underwood W; Pili R; Schwaab T Urology; 2011 Sep; 78(3):595-600. PubMed ID: 21777963 [TBL] [Abstract][Full Text] [Related]
10. Prediction of response to combined immunotherapy with interferon-alpha and low-dose interleukin-2 in metastatic renal cell carcinoma: expression patterns of potential molecular markers in radical nephrectomy specimens. Miyake H; Sakai I; Muramaki M; Kurahashi T; Takenaka A; Fujisawa M Int J Urol; 2009 May; 16(5):465-71. PubMed ID: 19467119 [TBL] [Abstract][Full Text] [Related]
15. Metastasectomy without systemic therapy in metastatic renal cell carcinoma: comparison with conservative treatment. Kwak C; Park YH; Jeong CW; Lee SE; Ku JH Urol Int; 2007; 79(2):145-51. PubMed ID: 17851285 [TBL] [Abstract][Full Text] [Related]
16. Solitary, isolated metastatic disease to the kidney: Memorial Sloan-Kettering Cancer Center experience. Adamy A; Von Bodman C; Ghoneim T; Favaretto RL; Bernstein M; Russo P BJU Int; 2011 Aug; 108(3):338-42. PubMed ID: 21083638 [TBL] [Abstract][Full Text] [Related]